Effect of testosterone replacement therapy on bone mineral density in patients with klinefelter syndrome

Yonsei Medical Journal

Volumn 54, Issue 6, 2013, Pages 1331-1335

  Jo, Dae Gi ^a   Lee, Hyo Serk ^a   Joo, Young Min ^b   Seo, Ju Tae ^a  

^a Kwandong University College of Medicine   (South Korea)

^b Daewoo General Hospital   (South Korea)

Author keywords

Bone mineral density; Klinefelter syndrome; Testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ADULT; ANDROGEN THERAPY; ARTICLE; BODY MASS; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FOLLOW UP; HEMATOLOGY; HORMONE DETERMINATION; HUMAN; HYPOGONADISM; KARYOTYPE; KLINEFELTER SYNDROME; MALE; OSTEOPOROSIS; PHYSICAL EXAMINATION;

BONE MINERAL DENSITY; KLINEFELTER SYNDROME; TESTOSTERONE;

ADULT; BONE DENSITY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; KLINEFELTER SYNDROME; MALE; TESTOSTERONE;

EID: 84886466478     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2013.54.6.1331     Document Type: Article

References (17)

1. Seeman E. During aging, men lose less bone than women because they gain more periosteal bone, not because they resorb less endosteal bone. Calcif Tissue Int 2001;69:205-8.
2. Klinefelter HF. Background of the recognition of Klinefelter's syndrome as a distinct pathologic entity. Am J Obstet Gynecol 1973;116:436-7.
3. Seeman E, Melton LJ 3rd, O'Fallon WM, Riggs BL. Risk factors for spinal osteoporosis in men. Am J Med 1983;75:977-83.
4. van den Bergh JP, Hermus AR, Spruyt AI, Sweep CG, Corstens FH, Smals AG. Bone mineral density and quantitative ultrasound parameters in patients with Klinefelter's syndrome after long-term testosterone substitution. Osteoporos Int 2001;12:55-62.
5. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995; 16:87-116.
6. Horowitz M, Wishart JM, O'Loughlin PD, Morris HA, Need AG, Nordin BE. Osteoporosis and Klinefelter's syndrome. Clin Endocrinol (Oxf) 1992;36:113-8.
7. Seo JT, Lee JS, Oh TH, Joo KJ. The clinical significance of bone mineral density and testosterone levels in Korean men with nonmosaic Klinefelter's syndrome. BJU Int 2007;99:141-6.
8. Choi HR, Lim SK, Lee MS. Site-specific effect of testosterone on bone mineral density in male hypogonadism. J Korean Med Sci 1995;10:431-5.
9. De Rosa M, Paesano L, Nuzzo V, Zarrilli S, Del Puente A, Oriente P, et al. Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic hypogonadal men after prolonged testosterone treatment. J Endocrinol Invest 2001;24:246-52.
10. Stepan JJ, Burckhardt P, Hána V. The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status. Bone 2003;33:589-96.
11. Wang C, Swerdloff RS. Androgen replacement therapy. Curr Ther Endocrinol Metab 1997;6:331-7.
12. Wong FH, Pun KK, Wang C. Loss of bone mass in patients with Klinefelter's syndrome despite sufficient testosterone replacement. Osteoporos Int 1993;3:3-7.
13. Aminorroaya A, Kelleher S, Conway AJ, Ly LP, Handelsman DJ. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol 2005;152:881-6.
14. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a metaanalysis. Clin Endocrinol (Oxf) 2005;63:280-93.
15. Smith DA, Walker MS. Changes in plasma steroids and bone density in Klinefelter's syndrome. Calcif Tissue Res 1977;22 Suppl: 225-8.
16. Schubert M, Minnemann T, Hübler D, Rouskova D, Christoph A, Oettel M, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during longterm treatment of men with hypogonadism. J Clin Endocrinol Metab 2004;89:5429-34.
17. von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 2002;23:419-25.